Ithamar Turenne - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ithamar Turenne

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Anticancer Research|September 21, 2012

Gemcitabine-induced pulmonary toxicityDow-Chung Chi, Frances Brogan, Ithamar Turenne, et al.

British Journal of Haematology|December 17, 2016

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.

The Lancet. Oncology|December 26, 2017

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Anticancer Research|September 21, 2012

Gemcitabine-induced pulmonary toxicityDow-Chung Chi, Frances Brogan, Ithamar Turenne, et al.

British Journal of Haematology|December 17, 2016

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.

The Lancet. Oncology|December 26, 2017

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.

Pageof 1